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Abstract: The increase in consumption of “ultra-processed” foods has raised attention because of
the possible adverse effects deriving from the Maillard reaction leading to the formation of toxic
advanced glycation end-products (AGEs) during food processing. Additionally, the increasing trend
and consumption of sugar-added foods and sweetened beverages is related to the endogenous
formation of the same toxic compounds. However, ultra-processing in the context of food technology
can bring challenges as well as a wealth of opportunities. Indeed, re-processing of grape pomace,
a by-product of winemaking, can yield phenolic-rich fractions that efficiently counteract the effects
of AGEs. In this review, the process of endogenous and exogenous AGE formation is illustrated.
Then, the ability of grape phenolics to act as inhibitors of AGE formation is presented, including
the efficacy ranking of various individual compounds measured in vitro and the outcome of in vivo
double-blinded randomized crossover trials designed to prove the efficacy of grape phenolics as
inhibitors of protein carbonylation. Finally, a survey of model functional foods added with grape
phenolics, either to lower the dietary load of AGEs or to deliver antiglycation agents in vivo is listed
in order to highlight the opportunity to develop safe and tailor-made “anti-AGEs” food applications.
Keywords: advanced glycation end-products; Maillard reaction; Nε-(carboxymethyl) lysine; grape
phenolics
1. Endogenous Formation of Advanced Glycation End-Products (AGEs)
The process of non-enzymatic protein glycation plays a major role in a number of pathological
processes [1–7]. Protein glycation occurs slowly and continuously throughout the life span, causing the
accumulation of advanced glycation end-products (AGEs) in elderly people, which has been involved
in the pathogenesis of age-related diseases. Apart from elderly people, in diabetic people, insulin
resistance and hyperglycaemia accelerate the accumulation of AGEs, leading to early development of
comorbidities [1,2]. AGEs have also been found to be involved in cardiovascular diseases [2,3], chronic
renal diseases [4], chronic liver diseases and hepatocellular carcinoma [7].
The pattern of protein glycation in vivo is complex. This process is initiated by the reaction of a
carbonyl group from a reducing sugar, such as glucose, fructose or ribose, with free amino groups
of proteins to form Schiff bases, which then undergo an Amadori rearrangement. The resulting
Amadori products degrade further to form reactive α-dicarbonyls such as methylglyoxal, glyoxal and
3-deoxyglucosone. These harmful compounds can also be generated through other routes such as the
polyol pathway and lipid peroxidation. Then, α-dicarbonyls react with one single amino group of
the side chains of lysine and arginine or with the thiol group of cysteine in proteins or, alternatively,
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cross-link two of these residues. These reactions lead to the formation of various cross-linked adducts,
which are collectively called AGEs. The Amadori products can also rearrange directly to form AGEs
(Figure 1) [7,8].
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Figure 1. Schematic representation of non-enzymatic protein glycation. Details of these degradation
patterns have been reported elsewhere [7,8]. Legend for AGE abbreviations is reported in Box 1.
Box 1. Nomenclature for the most common AGEs.
GLYOXAL + LYSINE:
CML: Nε-(carboxymethyl) lysine
GLYOXAL + ARGININE:
G-DH1: Nδ-(3,4-dihydroxy-1-imidazolidin-2-yl) ornithine
G-DH2: 5-(4,5-dihydroxy-2-imino-1-imidazolidinyl) norvaline
CMA: Nω-(carboxymethyl) arginine
G-H1: Nδ-(5-hydro-4-imidazolon-2-yl) ornithine
G-H2: 5-(2-amino-5-hydro-4-imidazolon-1-yl) norvaline
G-H3: 5-(2-amino-4-hydro-5-imidazolon-1-yl) norvaline
CMO: Nδ-(carboxymethyl) ornithine
GLYOXAL + CYSTEINE:
CMC: S-(carboxymethyl) cysteine
GLYOXAL + TWO LYSINE RESIDUES:
GO D: glyoxal-lysine dimer, 6-{1-[(5S)-5-ammonio-6-oxido-6-oxohexyl]imidazolium-3-yl}-L-norleucine
GOLA: Nε-(2-{[(5S)-5-ammon o-6-oxido-6-oxohexyl] amino}-2-oxoethyl)-L-lysine
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Box 1. Cont.
GLYOXAL + ARGININE AND LYSINE:
GODIC: Nε-(2-{[(4S)-4-ammonio-5-oxido-5-oxopentyl]amino}-3,5-dihydro-4H-imidazol-4-ylidene)-L-lysine
METHYLGLYOXAL + LYSINE:
CEL: Nε-(carboxylethyl) lysine
METHYLGLYOXAL + ARGININE:
MG-H1: Nδ-(5-methyl-4-imidazolon-2-yl)-L ornithine
MG-H2: 2-amino-5-(2-amino-5-hydro-5-methyl-4-imidazolon-1-yl)pentanoic acid
MG-H3: 2-amino-5-(2-amino-4-hydro-4-methyl-5-imidazolon-1-yl)pentanoic acid
CEA: Nω-(carboxyethyl) arginine
THP: Nδ-(4-carboxy-4,6-dimethyl-5,6-dihydroxy-1,4,5,6-tetrahydropyrimidine-2-yl)-L-ornithine
ARGPYRIMIDINE: Nδ-(5-hydroxy-4,6-dimethylpyrimidine-2-yl)-L-ornithine
METHYLGLYOXAL + CYSTEINE:
CEC: S-carboxyethylcysteine
METHYLGLYOXAL + TWO LYSINE RESIDUES:
MOLD: methylglyoxal lysine dimer, 6-{1-[(5S)-5-ammonio-6-oxido-6-oxohexyl]-4-methyl-imidazolium-3-
yl}-L-norleucine
METHYLGLYOXAL + LYSINE AND ARGININE:
MODIC: 2-ammonio-6-({2–[4-ammonio-5-oxido-5-oxopently)amino]-4-methyl-4,5-dihydro-1H-imidazol-5-
ylidene}amino)hexanoate
3-DEOXYGLUCOSONE + LYSINE:
CML: Nε-(carboxymethyl) lysine
PYRRALINE: 6-(2-formyl-5-hydroxymethyl-1-pyrrolyl)-L-norleucine
FORMYLINE: 6-(2-formyl-1-pyrrolyl)-L-norleucine
3-DEOXYGLUCOSONE + ARGININE:
3DG-H1: Nδ-[5-hydro-5-(2,3,4-trihydroxybutyl)-4-imidazolon-2-yl] ornithine
3DG-H2: 5-[2-amino-5-hydro-5-(2,3,4-trihydroxybutyl)-4-imidazolon-1-yl] norvaline
3DG-H3: 5-[2-amino-4-hydro-4-(2,3,4-trihydroxybutyl)-5-imidazolon-1-yl] norvaline
3-DEOXYGLUCOSONE + TWO LYSINE RESIDUES:
DOLD: 1,3-di(Nε-lysino)-4-(2,3,4-trihydroxybutyl)-imidazolium
3-DEOXYGLUCOSONE + ARGININE AND LYSINE:
DOGDIC: Nε-{2-{[(4S)-4-ammonio-5-oxido-5-oxopentyl]amino}-5-[(2S,3R)-2,3,4-trihydroxybutyl]-3,5-
dihydro-4H-imidazol-4-ylidene}-L-lysinate
LYSYL-PYRROPYRIDINE: lysyl-3,3a,8,8a-tetrahydro-3a-hydroxy-2-(1,2-dihydroxyethyl)-
5 hydroxymethyl-2H-furo [3′,2: 4,5]pyrrolo-[2,3-c]-pyridinium
DEGRADATION OF AMADORI PRODUCTS
GLUCOSEPANE: 2-acetylamino-5-[(4-butyl-6,7-dihydroxy-4,5,6,7,8,8ahexahydroimidazo [4,5-b]azepin-2-
yl)amino]-pentanoic acid
PENTOSIDINE: 6-[2-[[(4S)-4-amino-5-hydroxy-5-oxopentyl] amino]-4-imidazo [4,5-
b]pyridinyl]-L-norleucine
GLUCOLD: 1,3-bis-(5-amino-5-carboxypentyl)-4-(1,2,3,4-tetrahydroxybutyl)-3H-imidazolium
CROSSLINES A and B N-diacetates: (3R,4S)-3,4-dihydroxy-5-[(1S or 1R,2S,3R)-1,2,3,4-
tetrahydroxybutyl]-1,7-bis[6-(N-acetyl-L-norleucyl)]-1,2,3,4-tetrahydro-1,7-naphthyridinium chloride
DOPDIC: Nε-{2-{[(4S)-4-ammonio-5-oxido-5-oxopentyl] amino}-5-[(2S)-2,3-dihydroxypropyl] 3,5-
dihydro-4H-imidazol-4-ylidene}-L-lysinate
VESPERLYSINE A: 6-hydroxy-1,4-di{6-(L-norleucyl)}-1H-pyrrolo[3,2-b] pyridinium
VESPERLYSINE B: 6-hydroxy-5-methyl-1,4-di{6-(L-norleucyl)}-1H-pyrrolo[3,2-b] pyridinium
VESPERLYSINE C: 5-hydroxymethyl-1,6-di{6-(L-norleucyl)}-1H-pyrrolo[3,4-b] pyridinium
AGEs are bound to proteins with high contents of lysine and arginine units and long half-lives such
as collagen, serum albumin, elastin, myelin, low density lipoprotein, plasminogen activator, fibrinogen,
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etc. These glycated proteins lose their functionality and are resistant to removal by proteolytic enzymes.
Accumulation of AGEs in the extracellular matrix causes abnormal cross-linking and results in a
decrease of elasticity in vessels leading to arterial stiffness.
In addition, AGE receptors (RAGE) are expressed on many cell types. AGE–RAGE interaction
leads to the generation of reactive oxygen species, inflammation, angiogenesis and proliferation
through various signal transduction pathways. The activation of RAGE stimulates the phosphorylation
of the extracellular signal-regulated kinases, finally resulting in the stimulation of transcription factor
NF-κB and the production of pro-inflammatory cytokines. In addition, the stimulation of RAGE
results in the activation of the transforming growth factor β (TGF-β) pathway and induces vascular
endothelial growth factor overexpression. Intracellular AGE formation can also lead to quenching of
nitric oxide and impaired function of growth factors [9].
In contrast, other AGE receptors (AGE-Rs) form a complex of distinct receptors, which are
responsible for the detoxification and clearance of AGEs [10–12]. A fundamental role in the AGE
detoxification system is also played by the enzymatic glyoxalase system, which comprises glyoxalase-I
and glyoxalase-II. Glyoxalase-I catalyses the conversion of α-oxo-aldehydes such as methylglyoxal
into the corresponding hemithioacethal S-D lactoylglutathion, using L-glutathione (GSH) as a
cofactor. Then, glyoxalase-II hydrolyses the reaction of S-D-lactoylglutathion to H2O and d-lactate,
with the regeneration of GSH [5]. Hence, both the glyoxalase inducers and competitive inhibitors,
which modulate the functionality of these systems, are of interest for the therapy of AGE-related
diseases [13].
2. Effect of Diet on the Formation of AGEs
Protein glycation known as the Maillard reaction also occurs in heat-treated foods, generating
AGEs that are then exogenously introduced with the diet [14]. AGEs are naturally present in
uncooked animal-derived foods, and cooking results in the formation of new AGEs within these
foods. Nε-(carboxymethyl) lysine (CML) level was found to be a useful marker of dietary AGE
content and chosen to characterize the AGE load of foods [7]. Investigation on CML content of
549 foods demonstrated that grilling, broiling, roasting, searing and frying accelerate new AGE
formation [15]. These modified proteins are resistant to digestion but can be fermented by the colonic
bacteria. Upon fermentation, AGEs form toxic compounds that promote the beginning or maintenance
of ulcerative colitis in the host. This latter inflammatory disease causes mucosal necrosis [16].
In vivo studies show that dietary AGEs directly correlate with circulating AGEs, such as CML,
as well as with markers of oxidative stress [17]. Accordingly, restriction of dietary AGEs in patients
with diabetes [18] reduces markers of oxidative stress and inflammation. Moreover, obese individuals
with metabolic syndrome were reported to have elevated serum AGEs that strongly correlate with
insulin resistance, oxidative stress and inflammation [19]. Interestingly, a diet low in AGEs does not
cause a major reduction in adiposity but improves insulin resistance in obese people with metabolic
syndrome and may decrease the risk of type 2 diabetes [18].
In another hypothesis, protein glycation also occurs in the intestine when foods and beverages
sweetened with high fructose corn syrup are consumed [20]. Then, in situ enteral formed AGEs
are absorbed and may contribute to inflammatory diseases via engagement of the pro-inflammatory
RAGEs. Animal models of high sugar consumption, in particular fructose, have reported AGE
accumulation in different tissues in association with peripheral insulin resistance and lipid metabolism
alterations. Thus, among the sugars mostly used for sweetening of foods and drinks, fructose might
represent the most hazardous one for AGE accumulation. Recent cross-sectional studies demonstrated
that the consumption of high fructose corn syrup or fructose-sweetened beverages is associated with
asthma and bronchitis in adults and with asthma in children [21,22].
A schematic view of the glycation process is shown in Figure 2, which also highlights the possible
roles played by grape pomace phenolics, which are discussed in the following paragraphs.
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Figure 2. Potential sites of action of grape pomace phenolics (GPP) in the glycation pathway. In the
food matrix during processing and in the intestinal lumen, GPP can inhibit α-dicarbonyl compounds
and AGE formation by acting as metal chelators, antioxidants and carbonyl trapping agents. Absorbed
GPP or their metabolites can exert the same activities in vivo; moreover, GPP can assist the detoxifying
process in vivo by acting as a glyoxalase inducer. GSH, reduced glutathione; NFκB, nuclear factor
kappa-light-chain-enhancer of activated B cells, TGF-β transforming growth factor β.
3. Detection f AGEs
The methods to detect AGEs in human tissues, biological fluids and foods are mostly based
on fluorescence spectroscopy, chromatography, or immunoassay-based procedures. Fluorescence
spectroscopy can only detect fluorescent AGEs, among which the most studied are pentosidine,
crosslines A and B, argpyrimidine, vesperlysines A, B, and C, and lysyl-pyrropyridine. The excitation
wavelength for AGEs is generally between 300 nm and 420 nm and the emission wavelength is between
350 nm and 600 nm [23,24].
For chromatographic methods, the sample needs to be hydrolysed because most AGEs are not free
but bound to proteins. To detect bound AGEs, acid hydrolysis or enzymatic hydrolysis has been applied.
For the first approach, samples are first reduced in NaBH4 solution to prevent fructoselysine from
converting to CML; trichloroacetic acid or chloroform-methanol (2:1, v:v) is then used to precipitate
proteins before hydrolysis in 6 M HCl solution at 110 ◦C, followed by solid-phase extraction to purify
the hydrolysate. Enzymatic hydrolysis prevents destruction of AGEs (such as pyrraline) that are not
stable under acidic conditions. The enzymes used are pepsin, pronase E, prolinase and aminopeptidase
M, respectively [23]. Then, gas chromatography-mass spectrometry (GC-MS) and high-performance
liquid chromatography (HPLC) or ultra-performance liquid chromatography (UPLC) coupled with
diode array detector (DAD), fluorescence detector (FLD), mass spectrometry (MS) or tandem mass
spectrometry (MS/MS) are applied for the identification of the hydrolysed compounds. A FLD
provides higher sensitivity that a DAD. However, while fluorescent AGEs can be detected directly,
non-fluorescent AGEs require derivatization [25]. Alternatively, MS and tandem MS detectors do not
require derivatization and are highly sensitive [26].
AGEs are immunogenic and hence another approach for their detection is by immunochemical
methods. Both polyclonal and monoclonal antibodies to AGEs are commercially available. Among
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monoclonal antibodies, anti-pentosidine, anti-3-DG-H, anti-CML, anti-CEL, anti-pyrraline, anti-CMA
and anti-human RAGE are commercially available [24].
4. Grape Pomace Phenolics as Inhibitors of Protein Glycation—Mechanisms of Action
Phenolic compounds are found to inhibit protein glycation. The inhibitory effect could be
related to their metal chelation activity, since the Maillard reaction is promoted by metal ions [27].
The inhibitory mechanism of phenolics against glycation is also due to their antioxidant properties.
In fact, protein glycation is accompanied by oxidative reactions, whose occurrence was proven
by using phenyl-tert-butyl-nitron as a spin-trapping agent and monitoring the time course of the
reaction by electron spin resonance [28]. Moreover, phenolics also act as carbonyl trapping agents [29].
For flavonoids, the structural requirements for maximum anti-glycation activity, are not the same as
for antioxidant activity. Indeed, the antiglycation activity of phenolic-rich extracts from various plants
is not correlated to their antioxidant activity [30]. The structure–activity relationship of flavonoids in
scavenging reactive methylglyoxal was thoroughly investigated using model flavonoid molecules [31].
This latter study evidenced that: (1) the A ring is the active site of flavonoids in contributing to the
methylglyoxal trapping efficacy, and the hydroxyl group at C-5 on the A ring enhances the trapping
efficacy; (2) the double bond between C-2 and C-3 on the C ring could facilitate the trapping efficacy;
and (3) the number of hydroxyl groups on the B ring does not significantly influence the trapping
efficacy (Figure 3). Additionally, based on LC-MS studies, it was hypothesized that methylglyoxal
conjugation should occur at positions C-6 and C-8 of the A ring [31,32].
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Figure 3. Common structure of flavonoids consisting of C(6)–C(3)–C(6) skeleton containing two
aromatic rings (A,B) and one heterocyclic ring (C) with an oxygen atom (on the left) and the structure of
quercetin (on the right), a member of the flavonoid family possessing the best structural requirements
for α-dicarbonyl trapping ability (i.e., the hydroxyl group at C-5 on the A ring and the double bond
between C-2 and C-3 on the C ring) [31].
Grape pomace, which is the main by-product of winemaking constituted by skins and seed,
is a rich source of flavonoids. The current knowledge on the possible antiglycation activity of grape
pomace phenolics was investigated by analysing the literature of the last 10 years indexed by the
Scopus and Web of Science databases, using the search term “glycation” in combination with the terms
“grape”, or “proanthocyanidin”, “anthocyanin”, “quercetin”, “epicatechin”, “catechin”, “resveratrol”.
Grape pomace phenolics are mainly comprised of the polymeric flavonoids proanthocyanidins and the
monomeric flavanols, anthocyanins and flavonols and, in minor amounts, phenolic acids and stilbenes.
Methylglyoxal trapping ability was demonstrated for both red and white grape skin extracts and found
to be higher in red grape skin when compared with white grape skins. For red grape skin extracts
of various grape varieties, a significant correlation was found among the carbonyl trapping ability,
total phenolic content and antioxidant capacity. However, for white grape skin extract from various
grape varieties no correlations were observed, which suggests that other compounds were involved in
the carbonyl trapping activity and/or synergism among phenolic compounds [33]. In fact, the study
of model flavonoid molecules showed that they exert additive methyl glyoxal-trapping effects [31].
Hence, evaluation of the effectiveness of a complex pool of phenolics can reveal the most promising
food sources.
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The ability of grape skin phenolics to protect proteins from glycation was demonstrated by a model
system composed of bovine serum albumin (BSA) as a protein target and fructose or methylglyoxal
as glycating agents. In fact, isoelectric focusing proved that grape phenolics are able to protect the
target protein from charge variation that occurs at the beginning of the glycation, due to the reaction of
amino groups with fructose. Sodium dodecyl sulfate (SDS)-electrophoresis also provided evidence of
the effectiveness of grape phenolics in inhibiting structural damage of BSA, since they prevent the
formation of crosslinking among proteins that occurs at a later stage of the glycation reaction [34].
Fluorescence was evaluated to monitor the time course of the glycation reaction, revealing that the
phenolic extracts from red and white grape skins have higher anti-glycation activity than those of
commercial nutraceutical preparations. By using standard compounds, the following efficacy ranking
was observed for anti-glycation activity: quercetin 3-O glucoside > malvidin 3-O glucoside > catechin
> procyanidin A2. Interestingly, all grape skin phenolics were much more efficient than the synthetic
inhibitor aminoguanidine. Cinnamon, sage and rosemary, were also found to be efficient antiglycation
agents, but grape skin phenolics are more cost-effective [35].
5. Grape Pomace Phenolics as Inhibitors of Protein Glycation—In Vivo Studies
The effects of grape phenolics as inhibitors of protein carbonylation was investigated in seven
in vivo randomized crossover trials (Table 1). In the first study, 15 healthy subjects received a red
grape skin extract powder that delivered 31 mg/day of total phenolic compounds, for two weeks.
Following grape skin extract intake, there was an increase in activities of some enzymes involved in
antioxidant defense, namely, the glutathione reductase and peroxidase. No effects were observed on
2-aminoadipic semialdehyde, a plasma protein oxidation product as well as on malonyldialdehyde,
a marker of lipoprotein oxidation [36], but the amount of grape skin polyphenols assumed daily was
low compared to that used in later studies.
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Table 1. In vivo studies on the inhibitory effects of grape phenolics on protein carbonylation.
Product and Daily Dose Intake of Phenolics (Per Day) Subjects Trial Type Duration Outcome Ref
Red grape skin extract powder
(600 mg) Total phenolic 31 mg
n = 15
Healthy
Crossover
randomized 2 weeks
>Glutathione reductase activity and
glutathione peroxidase activity
No effect on superoxide dismutase or
catalase
No effect on 2-aminoadipic
semialdehyde, a plasma protein
oxidation product
No effect on malondialdehyde, a marker
of lipoprotein oxidation.
[36]
Grape seed extract 2 tablets Total phenolics 0.6 g n = 32Type-2 diabetic subjects
Crossover
randomized,
double-blind,
placebo-controlled
4 weeks
<Fructosamine
>High sensitivity C reactive protein
>Reduced glutathione
[37]
Grape phenolics or grape
phenolics + resveratrol 350 mg
~25 mg anthocyanins, ~1 mg
flavonols, ~40 mg
procyanidins, and ~0.8 mg
hydroxycinnamic acids, or the
same + 8.1 mg resveratrol
n = 75
Patients with stable
coronary artery disease
Crossover
randomized,
triple-blind,
placebo-controlled
1 year
>Serum adiponectin
<Plasminogen activator
>Inhibitor type 1
<Atherothrombotic signals in peripheral
blood mononuclear
No effect on glycated haemoglobin
[38]
Grape polyphenols 6 capsules Total phenolics 2 g
n = 38
Healthy
overweight/obese
first-degree relatives of
type-2 diabetic subjects
Crossover
randomized,
double-blind,
placebo-controlled
8 weeks
<Urinary F2-isoprostanes, muscle
thiobarbituric acid reactive substances,
muscle protein carbonylation
>Hepatic insulin sensitivity
[39]
Red grape pomace (20 g) Total phenolics 0.82 g n = 38Metabolic syndrome
Crossover
randomized,
placebo-controlled
16 weeks <Carbonyl groups in plasma proteins(protein damage) [40]
Pure compounds Trans-resveratrol (90 mg) +hesperidine (120 mg)
n = 29
Overweight and obese
subjects
Crossover
randomized,
double-blind,
placebo-controlled
8 weeks
>Expression and activity of glyoxalase-1
<Plasma methylglyoxal and total body
methylglyoxal-protein glycation
<Fasting and postprandial plasma
glucose
>Insulin sensitivity
>Markers for vascular health
[41]
Pure compounds Quercetin 3-glucoside (160 mg)(−)-epicatechin (100 mg)
n = 37
Healthy
Crossover
randomized,
double-blind,
placebo-controlled
4 weeks
<Plasma methylglyoxal for quercetin
3-glucoside, no change in glyoxal,
3-deoxyglucosone and free and
protein-bound AGE
No effect for epicatechin
[42]
Nutrients 2019, 11, 1917 9 of 16
In fact, in a successive intervention study, 32 type-2 diabetes mellitus patients received a grape
seed extract delivering 0.6 g⁄day of total phenolics or placebo for four weeks. Following grape seed
extract intake (but not placebo), there was a significant improvement in the markers of inflammation
and glycaemia and oxidative stress such as total antioxidant status and fructosamine [37].
In contrast, a lower amount of grape polyphenols was supplemented to 75 patients with stable
coronary artery disease for a one-year study. In this approach, the aim was to investigate specifically
the role of resveratrol, hence one group of patients was given 66.8 mg/day of grape phenolics without
resveratrol and another group was given the same amount of grape phenolics along with 8.1 mg/g of
resveratrol, while a third group (control) was given neither grape phenolics nor resveratrol. In subjects
who received resveratrol and other grape phenolics, the anti-inflammatory protein serum adiponectin
increased, plasminogen activator inhibitor type 1 increased and atherothrombotic signals in peripheral
blood mononuclear cells were inhibited. The presence of resveratrol among grape phenolics appeared
essential to exert these effects. However, no effect was observed on glycated haemoglobin content [38],
which could be due to the low amount of polyphenols given to the patients [38].
In a later study, 38 first-degree relatives of type-2 diabetic patients were supplemented with a
high-fructose diet along with 2 g/day of grape polyphenols in microcrystalline cellulose capsules or a
placebo for nine weeks. Results from this study demonstrated that grape phenolics protect against
fructose-induced oxidative stress, protein carbonylation and lipid peroxidation, and help prevent
insulin resistance [39].
Then, a study was performed on 38 subjects with at least one diagnostic criterion of metabolic
syndrome. The intervention group received 20 g/day of red wine grape pomace as a food supplement,
consisting of 10 g of dietary fibre, and 0.8 g of polyphenols. Both groups maintained their regular
eating habits and lifestyles. The inclusion of grape pomace in a regular diet improved blood pressure,
glycaemia and postprandial insulin and decreased oxidative protein damage [40].
In another approach, 29 overweight and obese subjects were involved in an intervention study
with capsules of trans-resveratrol (90 mg/day), which is found in grapes and hesperidin (120 mg/day),
which is present in oranges or placebo capsules for eight weeks. Before this clinical trial, the combination
of these two bioactive compounds was optimized in a cell study based on their ability as glyoxalase-1
inducers. Results from the clinical trial confirmed that the combination of both bioactive compounds
increased expression and activity of glyoxalase-1, decreased plasma methylglyoxal and total body
methylglyoxal-protein glycation, and decreased fasting and postprandial plasma glucose, while it
increased insulin sensitivity and improved markers for arterial health. However, in previous clinical
evaluations, trans-resveratrol and hesperidin used individually were ineffective [41].
Finally, 37 apparently healthy, non-smoking adults were involved in an intervention study with
two bioactive compounds that are quite abundant in grapes (i.e., (−)-epicatechin (100 mg/day), quercetin
3-glucoside (160 mg/day)) or placebo capsules for periods of four weeks. This study demonstrated
that quercetin, but not epicatechin, decreased plasma methylglyoxal concentrations. Quercetin may
potentially form a new treatment strategy for diseases in which methylglyoxal is involved [42].
All together these studies demonstrate that grape phenolics can play a role in the defense system
against protein glycation, although further information on the synergism among these bioactive
molecules is needed to provide mechanistic insights on the role of grape phenolics.
6. Food Formulation with Grape Pomace Phenolics as a Strategy to Counteract AGE Formation
Food formulation strategies with grape pomace phenolics have been proposed to counteract
AGEs formation in foods. Bakery products are among the most studied foods in which AGEs can be
generated through intensive heat treatment. CML level was found to be 35 mg/kg in bread crust [43].
In another study, CML level was found to be 49.72 mg/kg in bread crust and 15.09 mg/kg in bread
crumbs [44]. In addition to the intensity of heat treatment, the ingredients used play an important role
in CML formation, as evidenced from a study in which a basic muffin recipe was modified to assess
the effect of individual ingredients on AGE formation [30]. The basic mixture of wheat flour, water,
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sugar and fat in the ratio usually used for preparing muffins generated a CML level of 26.55 mg/kg
muffins. The sugar type has a fundamental importance in AGE formation: the muffins made with
glucose had the highest levels and approximately 3.5-fold greater content than those with fructose;
the muffins made with raw cane sugar produced about 11.5-fold higher concentrations of CML than
the white beet sugar-formulated muffins, probably due to higher levels of metal ions than white beet
sugar, which promote the Maillard reaction. The degree of unsaturation of the oils also influenced the
total amount of CML formed. In fact, the highest content of CML was detected in the muffins made
with grapeseed oil, while the lowest content of CML was found in samples made with olive oil [30].
In view of grape phenolic efficacy as an antiglycation agent, some studies have proposed the
use of grape phenolics in food matrices in order to decrease process-induced AGE formation and
hence, AGE load with foods (Table 2). In one study, 2 g/kg grape seed extract powder was used
in bread to prevent AGE formation during cooking. This incorporation of grape seed extract led
to a favourable change in the colour of bread without causing significant changes in other sensory
properties, and decreased CML level by 50% [43]. In following studies, the addition level of phenolics in
bakery products was increased by more than 10-fold. Purified phenolics, namely, quercetin, naringenin,
epicatechin, rosmarinic acid and chlorogenic acid were used at a level of 25 g/kg in a model cookie.
Among these compounds, quercetin was found to be the most efficient in the inhibition of both
glyoxal and fluorescent AGEs, while the impact on sensory properties was not evaluated [45]. Purified
phenolics, namely, quercetin, gallic acid, ferulic acid and caffeic acid were also separately used in bread
processing at levels in the range 1–20 g/kg. All phenolics tested were found to significantly reduce CML
by 31.77%–87.56% even at the lowest concentration, with catechin being the most efficient. The sensory
properties were not evaluated but it was hypothesized that the addition may adversely affect bread
flavour, because it reduces the formation of pyrazines [44]. Alternatively, the whole dried pomace of
red grape was added to a muffin recipe at 200 g/kg and was found to be effective in decreasing CML
level with no significant changes in the sensory profile [30].
Another approach was to formulate grape phenolics in foods in order to recover high amounts of
anti-glycation agent in the final product, which could potentially be absorbed and deliver antiglycation
agents to the body. However, a significant loss of phenolics occurs during the cooking process. In fact,
in bread with added grape phenolics, the loss of catechin, quercetin, gallic acid, ferulic acid and caffeic
acid are 51%, 49%, 86%, 75% and 47%, respectively [44]. Hence, high levels of phenolics need to be
incorporated to obtain significant residual amounts in the final product. Quercetin was added to
bread at levels of 12–36 g/kg in order to develop a promising functional food with high antiglycation
properties. However, by increasing the addition level of quercetin from 12 to 36 g/kg, there was a
progressive negative impact on the steamed bread volume, which significantly decreased, as well as
on the bread crumb texture, which increased in hardness. In contrast, incorporation levels below 1.20%
had no impact. Moreover, within an enrichment in the range of 12 and 36 g/kg, quercetin negatively
affected the yeast activity with significantly less CO2 produced in dough during proofing [46].
Alternatively, food matrices, such as tomato sauce and apple juice have very low AGEs content [15]
indicating that they are not prone to AGE formation during processing, and hence can be used as
vehicles for antiglycation agents.
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Table 2. Use of grape pomace-derived phenolics to inhibit AGE formation in foods or to increase the potential antiglycation activity of foods.
Food Phenolic Source Identified Phenolics Outcome Ref.
Wheat bread Grape seed extract powderIntegration: 2 g/kg bread n.d.
CML level was 35 mg/kg in the bread
crust of the control
Addition of grape seed extract caused a
50% decrease in CML level
[43]
Wheat bread Purified phenolicsIntegration: 1–20 g/kg flour
Flavanol: catechin
Flavonol: quercetin
Phenolic acids: gallic acid, ferulic acid, caffeic acids
CML level was 49.71 mg/kg in the bread
crust of the control and 15.09 mg/kg in
the bread crumb of the control
Phenolics were found to significantly
reduce CML (31.77%–87.56%)
[44]
Model cookie Purified phenolicsIntegration: 25 g/kg
Flavonol: quercetin
Flavanone: naringenin
Flavanol: epicatechin
Phenolic acids: rosmarinic acid, chlorogenic acid
Inhibition of fluorescent AGE formation
was 80% for quercetin and <20% for
naringenin, epicatechin, rosmarinic acid,
chlorogenic acid
[45]
Muffin Red grape pomaceIntegration: 200 g/kg
Phenolic acids: gallic acid
Flavanols: catechin, epicatechin, oligomeric procyanidins
Flavonols: quercetin 3-β-d-glucoside
CML level in the control muffins was
0.79–25.55 mg/kg depending on the
receipt
Red grape pomace decreased the level of
CML up to 100%
[27]
Bread QuercetinIntegration: 12–36 g/kg Flavonol: quercetin
Quercetin conferred antiglycation activity
to bread [46]
Tomato puree White grape skinIntegration: 30 g/kg
Flavonols: rutin, quercetin 3-O-glucuronide, quercetin
3-O-glucoside, quercetin, kaempferol 3-O-galactoside,
kaempferol 3-O-glucuronide, kaempferol 3-O-glucoside,
kaempferol
Flavanone: naringenin
Flavanols: oligomeric procyanidins
Addition of grape skins caused a 2.5-fold
increase in the in vitro antiglycation
activity of tomato (8 mmol catechin
equivalents/kg in the fortified puree)
[47]
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Table 2. Cont.
Food Phenolic Source Identified Phenolics Outcome Ref.
Apple puree Red grape skin Integration: 30 g/kg
Anthocyanins: delphinidin 3-O-glucoside, cyanidin
3-O-glucoside, petunidin 3-O-glucoside, peonidin
3-O-glucoside, malvidin 3-O-glucoside
Flavanols: catechin, epicatechin, procyanidin B2, procyanidin
B1, oligomeric proanthocyanidins
Phenolic acids: chlorogenic acid
Dihydrochalcones: phloretin-2-O-xyloglucoside, phloridzin
Flavonols: quercetin 3-O-glucoside, quercetin
3-O-glucuronide, quercetin, kaempferol
Addition of grape skins caused a 2.0-fold
increase in the in vitro antiglycation
activity of apple puree (69 mmol
aminoguanidine equivalents/kg)
[48]
Alginate
microcapsules Red grape skin extract
Anthocyanins: delphinidin 3-O-glucoside, cyanidin
3-O-glucoside, petunidin 3-O-glucoside, peonidin
3-O-glucoside, malvidin 3-O-glucoside
Flavanols: catechin, epicatechin, procyanidin B2, procyanidin
B1
Flavonols: quercetin 3-O-glucoside, quercetin, kaempferol
The microbeads acted as pH-controlled
release system for anti-glycation agents [49]
n.d.: not determined; CML: Nε-(carboxymethyl) lysine.
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A tomato puree with increased antiglycation activity was developed by adding micronized white
grape skins at a level of 30 g/kg, achieving good liking scores by consumers. In this formulation,
pasteurization slightly affected soluble proanthocyanidin content, for which recovery greater than
70% was achieved, while total flavonol content was not affected. In fact, quercetin and kaempferol
glycosides and glucuronides decreased by about 30%, but the corresponding aglycones increased
and the total amount remained constant, indicating that the main degradation was deglycosylation.
As a result, the grape skin-fortified tomato puree had a 2.5-fold increase in the antiglycation activity
in vitro [47]. A beverage based on apple puree formulated with 30 g/kg of micronized red grape
skins was also developed, obtaining a good liking rate by consumers. Pasteurisation of apple puree
beverage added with grape skins did not affect phenolic content. However, one-month storage in
the temperature range 15–35 ◦C decreased the contents of anthocyanins, monomeric, dimeric and
oligomeric flavanols, while the content of chlorogenic acid, flavonols and dihydrochalcones were
unaffected. The antiglycation activity of the fortified apple puree was ~2-fold higher than the apple
puree and was retained after one-month storage at 15 ◦C [48].
Alternatively, grape skin phenolics were encapsulated in alginate hydrogel as a controlled release
matrix for antiglycation agents. The encapsulation efficiency was 68% and phenolics were almost
completely retained at pH (gastric pH). Despite some phenolics interacting with alginate, which resulted
in a decrease of their bioactivity, grape skinphenolics were almost completely released from the alginate
microbeads at pH 7.4 (intestinal pH) and could exert antiglycation activity in vitro [49].
7. Conclusions
The antiglycation properties of grape skin phenolics have been proven by chemical studies
elucidating their mechanism of action. Moreover, five randomized crossover trials have provided
evidence that grape phenolics can prevent protein carbonylation in vivo and therefore can reach and
protect target proteins. These studies open up a new challenge for healthy food formulation which is to
develop grape phenolic-enriched foods in order either to prevent AGEs formation during processing
and/or to deliver antiglycation compounds to the gut and human tissues. To advance knowledge
already acquired on this topic, further investigations should better clarify the synergistic action among
phenolic compounds in order to maximize their anti-AGE efficacy. Moreover, model systems should
be designed to unravel the role of the food matrix on grape phenolic efficacy, ultimately leading to
dietary strategies to prevent harmful consequences of AGEs formation.
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